Journal News

JBC: Targeting semen amyloid fibrils to reduce HIV infectivity

Courtney Chandler
Oct. 1, 2016

The human immunodeficiency virus, which attacks the immune system, affects more than 1.2 million people in the U.S. There aren’t any vaccines or cures. Instead, microbicides are used to help protect against the transmission of HIV from person to person. However, the process of transmission isn’t understood fully and can involve both viral and human factors that promote infection.

Gallic acid, or GA, coats the surfaces of amyloid fibrils in semen to prevent HIV infectivity enhancement and coats the peptide precursors to prevent fibril formation.IMAGE COURTESY OF JOSIE LORICCO

In a recent paper published in the Journal of Biological Chemistry, Nadia Roan of the University of California, San Francisco, and George Makhatadze of Rensselaer Polytechnic Institute described a small molecule that prevents a specific human factor from increasing the ability of HIV to cause infection.

Researchers know that the virus itself has many factors that help it infect new hosts. There are also human factors that play a role in the transmission of HIV and a person’s susceptibility to infection. One of these factors is the ordered accumulations of misfolded proteins called amyloid fibrils. These fibrils occur naturally in human semen and have been shown to increase HIV infectivity and decrease the effectiveness of anti-HIV microbicide treatments.

The infection-promoting fibrils have been observed in the semen of both healthy and HIV-infected men. Therefore, researchers want to identify compounds that disrupt the formation of these fibrils or rid them of their infectivity-enhancing properties and reduce the sexual transmission of the virus through semen.

The investigators, led by graduate student Josie LoRicco of Rensselaer Polytechnic Institute, used a screen of small molecules to identify compounds that altered the properties of specific amyloid fibrils in semen. One molecule that came out of the screen, gallic acid, further proved to be capable of reducing HIV infectivity in the presence of semen. “Gallic acid is a small molecule found naturally in many foods, including grapes and tea,” says Makhatadze.

LoRicco, Roan, Makhatadze and colleagues further investigated gallic acid’s properties. They used atomic force and confocal microscopies in addition to several quantitative assays to characterize the interaction between gallic acid and the fibrils. Surprisingly, gallic acid did not induce disassembly of the fibrils but instead bound to their surfaces.

The investigators conducted biophysical analysis of fibrils’ surface properties to understand the nature of the interaction. They demonstrated that gallic acid limits the ability of semen fibrils to enhance HIV infection by binding to the fibrils’ surfaces and neutralizing their surface charge. Additionally, the gallic acid-coated fibrils prevent the formation of new amyloid fibrils by binding the precursor components and changing their charge characteristics.

“Gallic acid appears to do two things,” explains Makhatadze. “First, it inhibits new fibril formation. Second, it interacts with pre-existing fibrils and renders them incapable of facilitating HIV infectivity.”

The investigators suggest that gallic acid may be a useful addition to multicomponent microbicides that target both viral and human factors involved in the promotion of HIV transmission and infection. Makhatadze suggests that “such combination microbicides will be more effective at preventing transmission compared to single-component microbicides.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Courtney Chandler

Courtney Chandler is a biochemist and microbiologist in Baltimore, Md., and a columnist for ASBMB Today.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Cholesterol regulatory genes predict liver transplant outcomes
Journal News

Cholesterol regulatory genes predict liver transplant outcomes

April 10, 2026

Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Journal News

Lipid signatures for a rare neurological disorder

April 10, 2026

Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Journal News

The dual role of asprosin in chronic fatty liver disease

April 8, 2026

Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Journal News

Catching tau in the act

April 2, 2026

Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.